These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 4052935)

  • 1. A randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine-unresponsive metastatic prostatic carcinoma.
    Torti FM; Shortliffe LD; Carter SK; Hannigan JF; Aston D; Lum BL; Williams RD; Spaulding JT; Freiha FS
    Cancer; 1985 Dec; 56(11):2580-6. PubMed ID: 4052935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of combination chemotherapy with fluorouracil (F), doxorubicin (A), and cisplatin (P) (Fap) in hormonally resistant metastatic prostatic adenocarcinoma.
    Lupera H; Droz JP; Piot G; Lapleige P; Fargeot P; Theodore C
    Oncology; 1989; 46(6):372-4. PubMed ID: 2587004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma.
    Shimaoka K; Schoenfeld DA; DeWys WD; Creech RH; DeConti R
    Cancer; 1985 Nov; 56(9):2155-60. PubMed ID: 3902203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly doxorubicin in endocrine-refractory carcinoma of the prostate.
    Torti FM; Aston D; Lum BL; Kohler M; Williams R; Spaulding JT; Shortliffe L; Freiha FS
    J Clin Oncol; 1983 Aug; 1(8):477-82. PubMed ID: 6668511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group.
    van Wijk FH; Aapro MS; Bolis G; Chevallier B; van der Burg ME; Poveda A; de Oliveira CF; Tumolo S; Scotto di Palumbo V; Piccart M; Franchi M; Zanaboni F; Lacave AJ; Fontanelli R; Favalli G; Zola P; Guastalla JP; Rosso R; Marth C; Nooij M; Presti M; Scarabelli C; Splinter TA; Ploch E; Beex LV; ten Bokkel Huinink W; Forni M; Melpignano M; Blake P; Kerbrat P; Mendiola C; Cervantes A; Goupil A; Harper PG; Madronal C; Namer M; Scarfone G; Stoot JE; Teodorovic I; Coens C; Vergote I; Vermorken JB;
    Ann Oncol; 2003 Mar; 14(3):441-8. PubMed ID: 12598351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small cell lung cancer.
    Umsawasdi T; Valdivieso M; Booser DJ; Barkley HT; Ewer M; MacKay B; Dhingra HM; Murphy WK; Spitzer G; Chiuten DF
    Cancer; 1989 Nov; 64(10):1995-2000. PubMed ID: 2553235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A trial of combination chemotherapy followed by hormonal therapy for previously untreated metastatic carcinoma of the prostate.
    Seifter EJ; Bunn PA; Cohen MH; Makuch RW; Dunnick NR; Javadpour N; Bensimon H; Eddy JL; Minna JD; Ihde DC
    J Clin Oncol; 1986 Sep; 4(9):1365-73. PubMed ID: 2943877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of advanced hormone-refractory prostate carcinoma with a combination of etoposide, pirarubicin and cisplatin.
    Naito S; Ueda T; Kotoh S; Kumazawa J; Itoh K; Sagiyama K; Omoto T; Andoh S; Hasegawa Y; Fujisawa Y
    Cancer Chemother Pharmacol; 1995; 35(3):225-9. PubMed ID: 7805181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
    McCaffrey JA; Hilton S; Mazumdar M; Sadan S; Heineman M; Hirsch J; Kelly WK; Scher HI; Bajorin DF
    J Clin Oncol; 1997 Jun; 15(6):2449-55. PubMed ID: 9196161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
    Gallion HH; Brunetto VL; Cibull M; Lentz SS; Reid G; Soper JT; Burger RA; Andersen W;
    J Clin Oncol; 2003 Oct; 21(20):3808-13. PubMed ID: 14551299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study.
    Thigpen JT; Blessing JA; DiSaia PJ; Yordan E; Carson LF; Evers C
    J Clin Oncol; 1994 Jul; 12(7):1408-14. PubMed ID: 8021731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin.
    Piver MS; Eltabbakh GH; Hempling RE; Recio FO; Blumenson LE
    Gynecol Oncol; 1997 Nov; 67(2):141-6. PubMed ID: 9367697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil.
    Laurie JA; Hahn RG; Therneau TM; Patel SR; Mailliard JA; Windschitl HE; Twito DI; Morton RF; Krook JE
    Cancer; 1992 Mar; 69(6):1440-4. PubMed ID: 1540881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate.
    Papandreou CN; Daliani DD; Thall PF; Tu SM; Wang X; Reyes A; Troncoso P; Logothetis CJ
    J Clin Oncol; 2002 Jul; 20(14):3072-80. PubMed ID: 12118020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. National Prostatic Cancer Project randomized trial.
    Murphy GP; Priore RL; Scardino PT
    Urology; 1988 Jul; 32(1):33-40. PubMed ID: 3291371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas.
    Edmonson JH; Ryan LM; Blum RH; Brooks JS; Shiraki M; Frytak S; Parkinson DR
    J Clin Oncol; 1993 Jul; 11(7):1269-75. PubMed ID: 8315424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin C (FAM') in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial.
    Kasimis BS; Miller JB; Kaneshiro CA; Forbes KA; Moran EM; Metter GE
    J Clin Oncol; 1985 Mar; 3(3):385-92. PubMed ID: 3838343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.
    Aisner J; Cirrincione C; Perloff M; Perry M; Budman D; Abrams J; Panasci L; Muss H; Citron M; Holland J
    J Clin Oncol; 1995 Jun; 13(6):1443-52. PubMed ID: 7751891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience with weekly doxorubicin (adriamycin) in hormone-refractory stage D2 prostate cancer.
    Rangel C; Matzkin H; Soloway MS
    Urology; 1992 Jun; 39(6):577-82. PubMed ID: 1615614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Problems in the clinical evaluation of chemotherapy for hormonally-unresponsive carcinoma of the prostate].
    Rinsho K; Ishikawa S; Nemoto S; Kano S; Koiso K
    Nihon Hinyokika Gakkai Zasshi; 1984 Feb; 75(2):229-32. PubMed ID: 6540324
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.